Fig. 1: PIAS2b-dsRNAi blocks growth of thyroid cancer cell lines from anaplastic origin but not those from poorly differentiated/ metastatic differentiated origin. | Nature Communications

Fig. 1: PIAS2b-dsRNAi blocks growth of thyroid cancer cell lines from anaplastic origin but not those from poorly differentiated/ metastatic differentiated origin.

From: dsRNAi-mediated silencing of PIAS2beta specifically kills anaplastic carcinomas by mitotic catastrophe

Fig. 1

a Schematic view of human PIAS2 exon/intron gene distribution to give the two full-length isoforms. Location of each primer set for RT-qPCR, and of the dsRNAi at the 3′ UTR of the beta isoform, is indicated. b The two PIAS2 protein isoforms contain similar domains (SAP and LXXLL; PINIT, SP-RING, SUMO-binding domain, nuclear-localization signal NLS) except at the C-terminal domain, where the PIAS2b isoform contains the serine (S)-rich domain, including a poly-S stretch. Yellow bars indicate the epitopes of the two antibodies; while mPIAS2 detects both isoforms, rPIAS2b detects only PIAS2b. c, d mRNA expression of PIAS2b and PIAS2a in thyroid tissues (NT, normal thyroid; MNG, multinodular goiter; PTC, papillary thyroid carcinoma; PDTC, poorly differentiated thyroid carcinoma; ATC, anaplastic thyroid carcinoma). Benign/PTC–paired tissues from a single patient are shown in d. e, f RT-qPCR of PIAS2 isoforms and protein detection in thyroid cancer cell lines transfected with non-target sequence (ns-dsRNAi) or PIAS2b sequence 1 (PIAS2b-dsRNAi-1). Original cancers for the cell lines were: FTC-238, metastatic FTC; B-CPAP, PDTC of papillary origin; 8305C, CAL-62, BHT-101, and MB-1 cell lines, ATC. g–i Time-course of cell growth in similarly transfected cell lines comparing PIAS2b-dsRNAi-1, −2, or both. Transfection efficiency is indicated by the hatched-bar at the left. Genotype of each cell line is indicated with the driver mutation highlighted (note that for TERT, TERTp is the promoter, and TERTm, the mRNA expression). c, d n indicated in the figure; e n = 3 independent experiments, g n = 3 (day 4)- 9, h n = 3 (combination)-12 (sequence 1)- 16 (sequence 2) independent experiments; i n = 3 or n = 12 (CAL-62) independent experiments. c Two-sided Kruskal–Wallis; e one-sided Mann–Whitney; g–i two-sided two-way ANOVA with repeated measures. Bar indicates means ± SEM; when significant the exact p value is indicated in the figure. c, d Own design from Biorenders templates Source data are provided as a Source Data file.

Back to article page